Evidence map›Paper›PMID 38267014›Full record

ArticleBiomacromolecules2024

FAP Targeting of Photosensitizer-Loaded Polymersomes for Increased Light-Activated Cell Killing.

Michal Skowicki, Dimitri Hürlimann, Shabnam Tarvirdipour, Myrto Kyropoulou, Cora-Ann Schoenenberger, Sandrine Gerber-Lemaire, Cornelia G Palivan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomacromolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Michal SkowickiDepartment of Chemistry, University of Basel, BPR 1096, Mattenstrasse 22, 4058 Basel, Switzerland.
Dimitri HürlimannDepartment of Chemistry, University of Basel, BPR 1096, Mattenstrasse 22, 4058 Basel, Switzerland.ORCID 0000-0002-9605-8498
Shabnam TarvirdipourDepartment of Chemistry, University of Basel, BPR 1096, Mattenstrasse 22, 4058 Basel, Switzerland.
Myrto KyropoulouDepartment of Chemistry, University of Basel, BPR 1096, Mattenstrasse 22, 4058 Basel, Switzerland.
Cora-Ann SchoenenbergerDepartment of Chemistry, University of Basel, BPR 1096, Mattenstrasse 22, 4058 Basel, Switzerland.
Sandrine Gerber-LemaireGroup for Functionalized Biomaterials, Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.ORCID 0000-0002-6519-2782
Cornelia G PalivanDepartment of Chemistry, University of Basel, BPR 1096, Mattenstrasse 22, 4058 Basel, Switzerland.ORCID 0000-0001-7777-5355
University of Basel · CHÉcole Polytechnique Fédérale de Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As current chemo- and photodynamic cancer therapies are associated with severe side effects due to a lack of specificity and to systemic toxicity, innovative solutions in terms of targeting and controlled functionality are in high demand. Here, we present the development of a polymersome nanocarrier equipped with targeting molecules and loaded with photosensitizers for efficient uptake and light-activated cell killing. Polymersomes were self-assembled in the presence of photosensitizers from a mixture of nonfunctionalized and functionalized PDMS-

Indexed as

EndopeptidasesMembrane ProteinsPhotosensitizing AgentsPolymersCell DeathCell Line, TumorFibroblast Activation Protein AlphaHumansRose BengalEndopeptidasesFibroblast Activation Protein AlphaMembrane ProteinsPhotosensitizing AgentsPolymersRose Bengal

Identifiers

PMID38267014
PMCPMC10865352
OpenAlexW4391187892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.